Introduction {#s1}
============

Lung cancers are pathologically classified into small-cell lung cancer (SCLC) and non-small-cell lung cancer (NSCLC). In Japan, SCLC accounts for approximately 10% in men and 7% in women of all lung cancer cases. The incidence rates of SCLC significantly decreased in both genders probably due to the decline in smoking prevalence \[[@R01]\]. SCLC is then classified into two stages, limited disease (LD) or extensive disease (ED), defined by the staging system of Veterans Administration Lung Study Group \[[@R02]\], for the purpose of optimal selection of treatment options: curative-intent chemo-radiation therapy or palliative chemotherapy alone. Despite of highly sensitive first-line regimen of platinum-based chemotherapy, SCLC is an aggressive tumor carrying poor prognosis with early systemic metastases and acquired drug resistance. According to Japanese population-based data in 2002 - 2006, 1-, 3- and 5-year relative survival rates among LD-SCLC were 66.2%, 27.2% and 21.4%, but those among ED-SCLC were only 34.8%, 5.0% and 2.7%, respectively \[[@R03]\].

Sarcopenia is characterized by accelerated loss of skeletal muscle quantity and quality, which leads to decreased physical performance and then adverse outcomes such as falls, frailty and death \[[@R04]\]. Several meta-analyses revealed that sarcopenic cancer patients were associated with postoperative complications, chemotherapy-induced toxicity, worse overall survival (OS) and disease-free survival, compared with non-sarcopenic cancer patients \[[@R05], [@R06]\]. Regarding SCLC, there were three single-institutional and retrospective studies that had investigated association between sarcopenia and prognosis \[[@R07]-[@R9]\]. They all suggested that sarcopenia was an independent prognostic factor. However, these studies included various stages and treatment strategies of SCLC patients, e.g. 30.7-45.3% of LD-SCLC and 29.1-45.3% of concurrent chemo-radiotherapy. Thus, it still remains uncertain whether sarcopenia is also a promising prognostic factor for a specific patient cohort of ED-SCLC treated with standard chemotherapy. On the other hand, visceral adiposity also has recently been drawing attention, but still remains controversial as a prognostic factor for survival of various malignancies. Visceral adipose tissue secrets various cytokines and cytokine-like factors, which potentially enhance cancer progression. However, there were various conflicting studies, indicating negative or positive associations between visceral adiposity and cancer survival \[[@R10]\]. There was no study investigating association of visceral adiposity with prognosis of SCLC. Compared with these indexes, body mass index (BMI) is much simpler, more widely used, and more easily calculated only by individual weight and height. However, BMI does not reflect individual components of body weight such as fat distribution, or muscle volume and quality. Although BMI has been suggested as an independent prognostic factor for advanced NSCLC \[[@R11]\], it still remains controversial as a prognostic factor for SCLC.

The primary objective of our study was to investigate the prognostic significance of sarcopenia and visceral adiposity in ED-SCLC. In this study, we used BMI, psoas muscle index (PMI), intramuscular adipose tissue content (IMAC) and visceral-to-subcutaneous fat ratio (VSR) as indicators of general obesity, muscle quantity, muscle quality and visceral adiposity, respectively.

Materials and Methods {#s2}
=====================

Patients and study design {#s2a}
-------------------------

This study retrospectively collected 128 patients ([Supplementary Material 1](#S1){ref-type="supplementary-material"}, [www.wjon.org](http://www.wjon.org)). This cohort was the same as that of our previous study \[[@R12]\]. The inclusion criteria were as follows: 1) Cytologically or histologically SCLC; 2) The first-line, cisplatin (CDDP) or carboplatin (CBDCA)-containing chemotherapy which had been initiated between September 2007 and March 2018 at Osaka Police Hospital; 3) Clinical stage IIIB or IV in the seventh lung cancer tumor-node-metastasis (TNM) classification and staging system published by the International Union Against Cancer (UICC) \[[@R13]\]; 4) Abdominal plain or enhanced computed tomography (CT) scan covering L3 level within 3 months, serum albumin concentration (mg/dL) and lactate dehydrogenase (LDH) (IU/L) in peripheral venous blood sampling within 2 weeks before the initiation of the first-line chemotherapy; and 5) No indication for curative-intent thoracic radiotherapy. We collected the following data: sex, age, BMI, smoking habits, Eastern Cooperative Oncology Group (ECOG) performance status (PS), distant metastases, venous blood test, treatment regimens, response of the first-line chemotherapy according to the Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1 \[[@R14]\], progression-free survival (PFS) and OS. Our definitions of response rate (RR), disease control rate (DCR), PFS and OS followed those in our previous studies \[[@R15], [@R16]\]. The data was cut-off on December 31, 2019. Our study was approved by the Osaka Police Hospital Ethics Committee and followed the Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement \[[@R17]\]. This study was conducted in compliance with the Helsinki Declaration.

CT image analysis {#s2b}
-----------------

Using cross-sectional pretreatment CT attenuation values at the level of transverse process of L3, SYNAPSE VINCENT software (Fujifilm Medical, Tokyo, Japan) automatically identified the bilateral psoas muscle area, visceral fat area and subcutaneous fat area, and then we manually corrected them. We also manually traced the bilateral multifidus muscles areas. The definitions and the Japanese sex-specific cut-off points of PMI \[[@R18]\], IMAC \[[@R19]\] and VSR \[[@R20]\] followed those of our previous studies \[[@R15], [@R16]\].

Data analyses {#s2c}
-------------

The methods of descriptions and comparisons of continuous, categorical and survival data followed our previous studies \[[@R21]\]. Briefly, these data were shown by median value with interquartile range (IQR), frequencies, median time (months) with 95% confidential intervals (CI) and Kaplan-Meier method, and subsequently compared by the Mann-Whitney U test, Fisher's exact test, and log-rank test, respectively. Relationships between BMI, PMI, IMAC and VSR were evaluated using Spearman's correlation analysis for continuous variables and the described by Spearman's rank correlation coefficient (rs). We used Bonferoni's method for multiple comparisons and P value was expressed as six-fold. Using multivariate Cox proportional hazards analyses adjusted by age (\< 75 vs. ≥ 75 years), serum albumin (≥ 3.5 vs. \< 3.5 g/dL) \[[@R22]\], LDH (≤ upper limit of normal range (UNL) vs. \> UNL) \[[@R23]-[@R25]\], c-stage (IIIB vs. IV) \[[@R22]\] and ECOG-PS (0 - 1 vs. 2 - 4) \[[@R26]\], we evaluated BMI, PMI, IMAC and VSR as a significant prognostic factor of PFS and OS, and then showed these results by hazard ratios (HRs) with 95% CI. The age of 75 years was selected because it is the cut-off age of the late-stage medical care system for the Japanese elderly. The BMI \< 18.5 vs. ≥ 18.5 was chosen as the nutritional cut-off level of underweight. P values less than 0.05 were considered statistically significant in this study. Using EZR (Saitama Medical Center, Jichi Medical University, Saitama, Japan) \[[@R27]\], which is a graphical user interface for R (The R Foundation for Statistical Computing, Vienna, Austria), we conducted all statistical analyses.

Results {#s3}
=======

We divided 128 patients into high and low BMI, PMI, IMAC and VSR. We experienced 108 deaths, and 121 progressive disease or death until the date of data cut-off. There was no significant difference in characteristics between two groups, except for age and proportion of sex and hypoalbuminemia between low and high VSR groups ([Tables 1](#T1){ref-type="table"}-[](#T2){ref-type="table"}[](#T3){ref-type="table"}[4](#T4){ref-type="table"}). We did not find any significant differences in OS and PFS between two groups according to BMI, PMI, IMAC and VSR ([Figs. 1](#F1){ref-type="fig"}, [2](#F2){ref-type="fig"}). As an independent prognostic factor of OS and PFS, none of BMI, PMI, IMAC and VSR was selected by multivariate Cox hazard proportional analyses with adjustment for age, serum albumin, LDH, c-stage and ECOG-PS ([Table 5](#T5){ref-type="table"}).

###### Baseline Characteristics According to BMI

                                            BMI                  P                    
  ----------------------------------------- -------------------- -------------------- ------------
  N                                         16                   112                  
  Backgrounds                                                                         
    Sex (N), men/women                      10/6                 91/21                0.10^a^
    Age (years)                                                                       
      Median (IQR)                          72.5 (67.8 - 76)     71.5 (64.8 - 78)     0.33^b^
      \< 75/≥ 75 years (N)                  9/7                  70/42                0.78^a^
    Smoking status, NS/Ex/CS/unknown        1/4/11/0             2/37/72/1            0.45^a^
    ECOG-PS, 0 - 1/2/3                      7/7/2                70/24/18             0.21^a^
    c-stage, IIIB/IV                        1/15                 18/94                0.46^a^
    Metastatic sites                                                                  
      Brain                                 2                    22                   0.74^a^
      Liver                                 6                    31                   0.56^a^
      Bone                                  3                    15                   0.70^a^
    BMI, median (IQR)                       16.9 (16.1 - 17.3)   23.1 (20.6 - 25.8)   \< 0.01^b^
  Treatment                                                                           
    Platinum-based, cisplatin/carboplatin   2/14                 29/83                0.35^a^
    Partner drugs, etoposide/irinotecan     0/16                 15/97                0.21^a^
    Efficacy                                                                          
      CR/PR/SD/PD/NE                        0/7/2/4/3            2/69/15/17/9         
      ORR (%)                               43.8                 63.4                 0.17^a^
      DCR (%)                               56.2                 76.8                 0.12^a^
    Second or later line (N)                7                    62                   0.43^a^
      Amrubicin (N)                         5                    44                   0.60^a^
      Topotecan (N)                         0                    13                   0.37^a^
      Irinotecan (N)                        0                    7                    0.60^a^
  Pretreatment laboratory data                                                        
    Albumin (g/dL)                                                                    
      Median (IQR)                          3.1 (2.8 - 3.9)      3.7 (3.2 - 3.9)      0.13^b^
      ≥ 3.5/\< 3.5 g/dL (N)                 6/10                 68/44                0.11^a^
    LDH (IU/L)                                                                        
      Median (IQR)                          266 (201 - 492)      286 (217 - 402)      0.94^b^
      \< ULN/≥ ULN                          6/10                 31/81                0.56^a^

^a^Fisher's exact test; ^b^Mann-Whitney U test. BMI: body mass index; CR: complete response; CS: current smoker; DCR: disease control rate; ECOG-PS: Eastern Cooperative Oncology Group-performance status; Ex: ex-smoker; IQR: interquartile range; NE: not evaluated; NS: non-smoker; ORR: overall response rate; PD: progressive disease; PR: partial response; SD: stable disease; ULN: upper limit of normal range; LDH: lactate dehydrogenase.

###### Baseline Characteristics According to PMI

                                            PMI                  P                    
  ----------------------------------------- -------------------- -------------------- ------------
  N                                         93                   35                   
  Backgrounds                                                                         
    Sex (N), men/women                      75/18                26/9                 0.47^a^
    Age (years)                                                                       
      Median (IQR)                          71 (66 - 76)         72 (63.5 - 79)       0.79^b^
      \< 75/≥ 75 years (N)                  59/34                20/15                0.55^a^
    Smoking status, NS/Ex/CS/unknown        1/29/62/1            2/12/21/0            0.43^a^
    ECOG-PS, 0 - 1/2/3                      51/25/17             26/6/3               0.15^a^
    c-stage, IIIB/IV                        14/79                5/30                 1.00^a^
    Metastatic sites                                                                  
      Brain                                 17                   7                    0.80^a^
      Liver                                 29                   8                    0.39^a^
      Bone                                  14                   4                    0.79^a^
    BMI                                                                               
      Median (IQR)                          21.0 (19.1 - 24.0)   24.6 (23.2 - 27.1)   \< 0.01^b^
      ≥ 18.5/\< 18.5                        78/15                34/1                 0.07^a^
  Treatment                                                                           
    Platinum-based, cisplatin/carboplatin   22/71                9/26                 0.82^a^
    Partner drugs, etoposide/irinotecan     81/12                32/3                 0.76^a^
    Efficacy                                                                          
      CR/PR/SD/PD/NE                        0/57/10/16/10        2/19/7/5/2           
      ORR (%)                               61.3                 60.0                 1.00^a^
      DCR (%)                               72.0                 80.0                 0.50^a^
    Second or later line (N)                46                   23                   0.12^a^
      Amrubicin (N)                         34                   15                   0.55^a^
      Topotecan (N)                         9                    4                    0.75^a^
      Irinotecan (N)                        5                    2                    1.00^a^
  Pretreatment laboratory data                                                        
    Albumin (g/dL)                                                                    
      Median (IQR)                          3.6 (3.0 - 3.9)      3.7 (3.3 - 3.9)      0.57^b^
      ≥ 3.5/\< 3.5 g/dL (N)                 49/44                25/10                0.07^a^
    LDH (IU/L)                                                                        
      Median (IQR)                          282 (218 - 410)      323 (205 - 410)      0.69^b^
      \< ULN/≥ ULN                          26/67                11/24                0.83^a^

^a^Fisher's exact test; ^b^Mann-Whitney U test. BMI: body mass index; PMI: psoas muscle index; CR: complete response; CS: current smoker; DCR: disease control rate; ECOG-PS: Eastern Cooperative Oncology Group-performance status; Ex: ex-smoker; IQR: interquartile range; NE: not evaluated; NS: non-smoker; ORR: overall response rate; PD: progressive disease; PR: partial response; SD: stable disease; ULN: upper limit of normal range; LDH: lactate dehydrogenase.

###### Baseline Characteristics According to IMAC

                                            IMAC                 P                    
  ----------------------------------------- -------------------- -------------------- ---------
  N                                         114                  14                   
  Backgrounds                                                                         
    Sex (N), men/women                      89/25                12/2                 0.73^a^
    Age (years)                                                                       
      Median (IQR)                          71.5 (66 - 76)       76.5 (66.5 - 81.8)   0.15^b^
      \< 75/≥ 75 years (N)                  72/42                7/7                  0.39^a^
    Smoking status, NS/Ex/CS                2/36/75/1            1/5/8/0              0.41^a^
    ECOG-PS, 0 - 1/2/3                      71/27/16             6/4/4                0.27^a^
    c-stage, IIIB/IV                        17/97                2/12                 1.00^a^
    Metastatic sites                                                                  
      Brain                                 24                   0                    0.07^a^
      Liver                                 31                   6                    0.23^a^
      Bone                                  17                   1                    0.69^a^
    BMI                                                                               
      Median (IQR)                          21.8 (19.5 - 24.5)   24.1 (22.9 - 25.7)   0.06^b^
      ≥ 18.5/\< 18.5                        98/16                14/0                 0.21^a^
  Treatment                                                                           
    Platinum-based, cisplatin/carboplatin   29/85                2/12                 0.52^a^
    Partner drugs, etoposide/irinotecan     99/15                14/0                 0.37^a^
    Efficacy                                                                          
      CR/PR/SD/PD/NE                        2/69/14/18/11        0/7/3/3/1            
      ORR (%)                               62.3                 50.0                 0.40^a^
      DCR (%)                               74.6                 71.4                 0.76^a^
    Second or later line (N)                62                   7                    0.78^a^
      Amrubicin (N)                         43                   6                    0.77^a^
      Topotecan (N)                         12                   1                    1.00^a^
      Irinotecan (N)                        7                    0                    1.00^a^
  Pretreatment laboratory data                                                        
    Albumin (g/dL)                                                                    
      Median (IQR)                          3.7 (3.1 - 3.9)      3.4 (2.9 - 3.8)      0.21^b^
      ≥ 3.5/\< 3.5 g/dL (N)                 68/46                6/8                  0.26^a^
    LDH (IU/L)                                                                        
      Median (IQR)                          285 (210 - 428)      292 (225 - 388)      0.79^b^
      \< ULN/≥ ULN                          33/81                4/10                 1.00^a^

^a^Fisher's exact test; ^b^Mann-Whitney U test. IMAC: intramuscular adipose tissue content; BMI: body mass index; CR: complete response; CS: current smoker; DCR: disease control rate; ECOG-PS: Eastern Cooperative Oncology Group-performance status; Ex: ex-smoker; IQR: interquartile range; NE: not evaluated; NS: non-smoker; ORR: overall response rate; PD: progressive disease; PR: partial response; SD: stable disease; ULN: upper limit of normal range.

###### Baseline Characteristics According to VSR

                                            VSR                  P                    
  ----------------------------------------- -------------------- -------------------- ----------
  N                                         72                   56                   
  Backgrounds                                                                         
    Sex (N), men/women                      52/20                49/7                 0.049^a^
    Age (years)                                                                       
      Median (IQR)                          69 (64.8 - 76)       73.5 (67.8 - 78.3)   0.04^b^
      \< 75/≥ 75 years (N)                  50/22                29/27                0.046^a^
    Smoking status, NS/Ex/CS                1/22/49/0            2/19/34/1            0.54^a^
    ECOG-PS, 0 - 1/2/3                      40/19/13             37/12/7              0.47^a^
    c-stage, IIIB/IV                        10/62                9/47                 0.80^a^
    Metastatic sites                                                                  
      Brain                                 15                   9                    0.65^a^
      Liver                                 20                   17                   0.85^a^
      Bone                                  10                   8                    1.00^a^
    BMI                                                                               
      Median (IQR)                          21.1 (19.1 - 24.3)   23.3 (20.9 - 26.2)   0.02^b^
      ≥ 18.5/\< 18.5                        60/12                52/4                 0.18^a^
  Treatment                                                                           
    Platinum-based, cisplatin/carboplatin   17/55                14/42                1.00^a^
    Partner drugs, etoposide/irinotecan     65/7                 48/8                 0.58a
    Efficacy                                                                          
      CR/PR/SD/PD/NE                        1/44/6/14/7          1/32/11/7/5          
      ORR (%)                               62.5                 58.9                 0.72^a^
      DCR (%)                               70.8                 78.6                 0.42^a^
    Second or later line (N)                37                   32                   0.59^a^
      Amrubicin (N)                         25                   24                   0.37^a^
      Topotecan (N)                         7                    6                    1.00^a^
      Irinotecan (N)                        5                    2                    0.47^a^
  Pretreatment Laboratory data                                                        
    Albumin (g/dL)                                                                    
      Median (IQR)                          3.4 (3.1 - 3.9)      3.8 (3.2 - 4.0)      0.15^b^
      ≥ 3.5/\< 3.5 g/dL (N)                 35/37                39/17                0.02^a^
    LDH (IU/L)                                                                        
      Median (IQR)                          270 (217 - 430)      304 (209 - 402)      0.63^b^
      \< ULN/≥ ULN                          21/51                16/40                1.00^a^

^a^Fisher's exact test; ^b^Mann-Whitney U test. VSR: visceral-to-subcutaneous fat ratio; BMI: body mass index; CR: complete response; CS: current smoker; DCR: disease control rate; ECOG-PS: Eastern Cooperative Oncology Group-performance status; Ex: ex-smoker; IQR: interquartile range; NE: not evaluated; NS: non-smoker; ORR: overall response rate; PD: progressive disease; PR: partial response; SD: stable disease; ULN: upper limit of normal range; LDH: lactate dehydrogenase.

![Kaplan-Meier curves of overall survival according to BMI (a), PMI (b), IMAC (c) and VSR (d). BMI: body mass index; PMI: psoas muscle index; IMAC: intramuscular adipose tissue content; VSR: visceral-to-subcutaneous fat ratio.](wjon-11-139-g001){#F1}

![Kaplan-Meier curves of progression-free survival according to BMI (a), PMI (b), IMAC (c) and VSR (d). BMI: body mass index; PMI: psoas muscle index; IMAC: intramuscular adipose tissue content; VSR: visceral-to-subcutaneous fat ratio.](wjon-11-139-g002){#F2}

###### Adjusted Hazard Ratios of Indexes of Sarcopenia and Visceral Obesity for Overall Survival and Progression-Free Survival

  Variables          PFS, HR (95% CI)     P      OS, HR (95% CI)      P
  ------------------ -------------------- ------ -------------------- ------
  BMI                                                                 
    ≥ 18.5           1 (reference)               1 (reference)        
    \< 18.5          1.36 (0.79 - 2.34)   0.27   1.47 (0.83 - 2.57)   0.18
  PMI (cm^2^/m^2^)                                                    
    High             1 (reference)               1 (reference)        
    Low              1.44 (0.94 - 2.19)   0.09   1.32 (0.84 - 2.07)   0.23
  IMAC                                                                
    Low              1 (reference)               1 (reference)        
    High             0.97 (0.51 - 1.84)   0.93   0.87 (0.45 - 1.69)   0.68
  VSR                                                                 
    Low              1 (reference)               1 (reference)        
    High             1.08 (0.73 - 1.59)   0.71   0.96 (0.63 - 1.47)   0.86

Multivariate adjustment for age (\< 75 vs. 5 75 years), serum albumin (≥ 3.5 vs. \< 3.5 g/dL), LDH (≤ UNL vs. \> UNL), c-stage (IIIB vs. IV) and ECOG-PS (0 - 1 vs. 2 - 4). BMI: body mass index; CI: confidence interval; ECOG-PS: Eastern Cooperative Oncology Group-performance status; HR: hazard ratio; IMAC: intramuscular adipose tissue content; LDH: lactate dehydrogenase; PMI: psoas muscle index; UNL: upper limit of normal range; VSR: visceral-to-subcutaneous fat ratio; PFS: progression-free survival; OS: overall survival.

Discussion {#s4}
==========

Our study did not find any significant associations of sarcopenia defined by muscle quantity, PMI, with OS and PFS in ED-SCLC. These findings were contrary to the previous retrospective Korean studies, in which various sarcopenic indexes, L3 muscle index, muscle index (MI) of pectoralis muscles + high NLR, and cachexia index categorized by L3 muscle and fat indexes, were independent prognostic factors of shorter OS \[[@R07]-[@R9]\]. As shown in [Table 6](#T6){ref-type="table"}, there were differences in definitions of sarcopenia, proportion of sarcopenic patients, sex balance, clinical stage and treatment between ours and previous studies \[[@R07]-[@R9]\]. Our study was characterized by sarcopenia sorted by PMI, higher proportion of sarcopenic patients (72.7%), lower proportion of man (78.9%), ED stage alone and standard chemotherapy alone. On the other hand, it is noteworthy that this was the first study investigating muscle quality indicated by IMAC in ED-SCLC. We could not detect any significant relationships of sarcopenia defined by IMAC with survivals in ED-SCLC. Therefore, our study indicated that neither muscle quantity nor quality affects prognosis of ED-SCLC.

###### Review of Studies That Evaluated CT-Determined Sarcopenia in SCLC

  Author (year)                 Patients                                                                                  Sarcopenia definitions                                               Survival comparison; sarcopenia vs. non-sarcopenia                        Multivariate analyses
  ----------------------------- ----------------------------------------------------------------------------------------- -------------------------------------------------------------------- ------------------------------------------------------------------------- ----------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Kim et al (2015) \[[@R07]\]   149 SCLC; male (85.2%), ED (67.8%), chemo alone (48.3%), CRT (29.5%), BSC alone (20.8%)   L3MI, sarcopenia (79.2%)                                             OS, 8.6 vs. 16.8 months, P = 0.031                                        Non-sarcopenia vs. sarcopenia; OS, HR 1.68, 95% CI 1.04 - 2.72, P = 0.034
  Go et al (2016) \[[@R08]\]    117 male SCLC; ED (54.7%), CRT (45.3%)                                                    SMI of pectoralis muscles, sarcopenia (24.8%)                        PFS, 6.0 vs. 7.5 months, P = 0.009; OS, 10.5 vs. 13.5 months, P = 0.052   Sarcopenia with low NLR + non-sarcopenia vs. sarcopenic with high NLR; PFS, HR 3.805, 95% CI 1.774 - 8.158, P = 0.001; OS, HR 2.230, 95% CI 1.048 - 4.743, P = 0.037
  Kim et al (2017) \[[@R9]\]    127 male SCLC; ED (69.3%), chemo alone (48.0%), CRT (29.1%), BSC alone (21.3%)            CS defined by L3MI and L3FI; CS0 (13.4%), CS1 (74.8%), CS2 (11.8%)   OS, 5.0 (CS2) vs. 8.9 (CS1) vs. 18.3 months (CS0), P = 0.007              CS0 vs. CS1, OS, HR 1.99, 95% CI 1.05 - 3.78, P = 0.036; CS0 vs. CS2, OS, HR 2.59, 95% CI 1.14 - 5.89, P = 0.023
  Ours (2020)                   128 ED-SCLC; male (78.9%), chemo alone (100%)                                             PMI; low PMI (72.7%)                                                 PFS, 4.5 vs. 5.2 months, P = 0.17; OS, 8.8 vs. 11.4 months, P = 0.17      High PMI vs. low PMI; PFS, HR 1.44, 95% CI 0.94 - 2.19, P = 0.09; OS, HR 1.32, 95% CI 0.84 - 2.07, P = 0.23

BSC: best supportive care; chemo: chemotherapy; CI: confidence interval; CRT: chemo-radiotherapy; CS: cachexia score; ED: extensive disease; FI: fat index; HR: hazard ratio; LD: limited disease; MI: muscle index; NLR: neutrophil-to-lymphocyte ratio; OS: overall survival; PFS: progression-free survival; PMI: psoas muscle index; SCLC: small-cell lung cancer; SMI: skeletal muscle index; CT: computed tomography.

Our study also denied association between visceral adiposity and prognosis of ED-SCLC. In a Korean study, cachexia scores, which categorized patients into three groups by combination of sarcopenia and/or adipopenia at L3 level, predicted prognosis in male SCLC patients. However, to our knowledge, ours was the first study that had directly focused on visceral adiposity in SCLC. Our results were consistent with our previous studies of NSCLCs treated with epidermal growth factor receptor-tyrosine kinase inhibitors \[[@R15]\] or with immune checkpoint inhibitor monotherapy \[[@R16]\]. Thus, our series of studies doubted visceral adiposity as a prognostic factor for various types of lung cancer.

Interestingly, our study also failed to detect BMI as a prognostic factor for ED-SCLC. Previous studies evaluating BMI and prognosis of SCLC were various in cut-off points of BMI, clinical stage, treatment and analytical methods \[[@R07]-[@R9], [@R28]-[@R31]\] ([Table 7](#T7){ref-type="table"}). Most studies failed to demonstrate significant association of BMI with survival prognosis of SCLC \[[@R07], [@R08], [@R28]-[@R30]\]. Our study was consistent with these previous studies. In multivariate analyses of a pooled analysis of international lung cancer consortium, none of underweight, overweight, obese at diagnosis, and decreased change in BMI from young adult age (18 - 25 years) to diagnosis was an independent prognostic factor for OS of SCLC. However, in NSCLC, among these BMI-related variables, underweight and decreased BMI change were significantly associated with poorer OS, while overweight and obese were with improved OS \[[@R31]\]. We previously detected significant association of low BMI (\< 18.5 kg/m^2^) with shorter PFS and OS in epidermal growth factor receptor (EGFR)-mutant NSCLC patients treated with EGFR-tyrosine kinase inhibitors (TKIs) \[[@R15]\]. Thus, there may be a difference in relations of BMI with survival between NSCLC and SCLC.

###### Review of Studies That Evaluated BMI in Untreated SCLC

  ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Author (year)                           Patients                                                                                  BMI                                                                                         Survival comparison                           Univariate analyses                                                                               Multivariate analyses
  --------------------------------------- ----------------------------------------------------------------------------------------- ------------------------------------------------------------------------------------------- --------------------------------------------- ------------------------------------------------------------------------------------------------- ---------------------------------------------------------------------
  Georgiadis et al (1995) \[[@R29]\]      262 SCLC; male (63%), ED (44%), chemo alone (61%), CRT (39%)                              Obese (27.1%), men ≥ 27.8, women ≥ 27.3; severely obese (10.7%), men ≥ 31.1, women ≥ 32.3   Not described in details, but insignificant   NA                                                                                                NA

  Kim et al (2015) \[[@R07]\]             149 SCLC; male (85.2%), ED (67.8%), chemo alone (48.3%), CRT (29.5%), BSC alone (20.8%)   ≥ 23 vs. \< 23 (59.1%)                                                                      NA                                            OS; HR 1.19 (95% CI 0.83 - 1.72), P = 0.340                                                       NA

  Go et al (2016) \[[@R08]\]              117 male SCLC; ED (54.7%), CRT (45.3%)                                                    ≥ 18.5 vs. \< 18.5 (10.3%)                                                                  NA                                            PFS, HR 1.749 (95% CI 0.930 - 3.291), P = 0.083; OS, HR 1.077 (95% CI 0.554 - 2.096), P = 0.827   PFS, 1.001 (0.500 - 2.006), P = 0.998; OS, not assessed

  Kim et al (2017) \[[@R9]\]              127 male SCLC; ED (69.3%), chemo alone (48.0%), CRT (29.1%), BSC alone (21.3%)            ≥ 18.5 vs. \< 18.5 (15.0%)                                                                  NA                                            OS, HR 2.32 (95% CI 1.38 - 3.89), P \< 0.001                                                      NA

  Abdel-Rahman (2018) \[[@R28]\]          455 ED-SCLC in a phase III trial; male (72.5%), CBDCA + VP-16 (100%)                      \< 25 (48.1%) vs. ≥ 25                                                                      NA                                            PFS, HR 0.891 (95% CI 0.644 - 1.234), P = 0.487; OS, HR 0.856 (95% CI 0.678 - 1.082), P = 0.194   PFS, OS; NA

  Shen et al (2019) \[[@R30]\]            178 SCLC; male (79.78%), ED (71.91%), VP-16 containing chemo alone                        18.5 - 24 (56.74%) vs. \< 18.5 (6.74%) vs. ≥ 24                                             P = 0.4107                                    PFS, 18.5 - 24 vs. \< 18.5, P = 0.851; 18.5 - 24 vs. ≥ 24, P = 0.212                              NA

  Shepshelovich et al (2019) \[[@R31]\]   2,787 SCLC from 16 studies; male (56%), ED (59%),                                         \< 18.5 vs. normal                                                                          OS (ED), P \< 0.001;\                         HR 1.16 (95% CI 0.89 - 1.51), P = 0.28                                                            HR 1.20 (95% CI 0.92 - 1.6), P = 0.18
                                                                                                                                                                                                                                OS (LD), P = 0.002                                                                                                                              

                                          25 - 30 vs. normal                                                                                                                                                                    HR 0.97 (95% CI 0.87 - 1.07), P = 0.51        HR 0.93 (95% CI 0.84 - 1.0), P = 0.20                                                             

                                          \> 30 vs. normal                                                                                                                                                                      HR 1.05 (95% CI 0.94 - 1.19), P = 0.39        HR 1.07 (95% CI 0.95 - 1.2), P = 0.24                                                             

  Ours (2020)                             128 ED-SCLC; male (78.9%), chemo alone (100%)                                             ≥ 18.5 vs. \< 18.5 (12.5%)                                                                  PFS, P = 0.39; OS, P = 0.07                   NA                                                                                                PFS, 1.36 (0.79 - 2.34), P = 0.27; OS, 1.47 (0.83 - 2.57), P = 0.18
  ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

BSC: best supportive care; CBDCA: carboplatin; Chemo: chemotherapy; CI: confidence interval; CRT: chemo-radiotherapy; ED: extensive disease; LD: limited disease; HR: hazard ratio; NA: not accessed; OS: overall survival; PFS: progression-free survival; SCLC: small-cell lung cancer; VP-16: etoposide; BMI: body mass index.

Some limitations existed in this study. First, our small sample size and single-centered retrospective study design are not enough for our results to be generalized for all ED-SCLC patients. We included imbalance and small number of group patients especially in BMI and IMAC. We might miss unmeasured confounding variables, such as, nutritional status of eating or body weight change. However, our study currently denies patient selection for chemotherapy according to sarcopenia and visceral adiposity. Second, our patients had received conventional chemotherapy of platinum doublet regimen before atezolizumab with carboplatin and etoposide was approved by Japanese medical insurance in August 2020. Our study did not reflect the new era of combination immunotherapy for ED-SCLC. Further studies will be warranted for combination immunotherapy for ED-SCLC. Third, our definitions of sarcopenia and visceral adiposity were not standard, but convenient. For cancer patients, pretreatment staging CT scans are common. CT-determined definition of sarcopenia is much easier to use than standard and authorized diagnostic definitions requiring multiple steps \[[@R04], [@R32]\]. The standard definition of visceral adiposity remains indefinite. CT-defined visceral adiposity is more reliable than conventional method of waist circumference measurement.

Conclusions {#s4a}
-----------

Neither pretreatment sarcopenia nor visceral adiposity is a prognostic marker of patients with ED-SCLC treated with standard regimen of platinum-based chemotherapy.
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